Suppr超能文献

复方新诺明用于疟疾流行地区儿童发热性疾病

Co-trimoxazole for childhood febrile illness in malaria-endemic regions.

作者信息

Bloland P B, Redd S C, Kazembe P, Tembenu R, Wirima J J, Campbell C C

机构信息

Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control, Atlanta, Georgia 30333.

出版信息

Lancet. 1991 Mar 2;337(8740):518-20. doi: 10.1016/0140-6736(91)91299-a.

Abstract

The efficacy of co-trimoxazole for the treatment of Plasmodium falciparum parasitaemia in children younger than 5 years of age was evaluated in Malawi. 46 children with P falciparum parasitaemia, 37% of whom also met clinical criteria for a diagnosis of acute lower respiratory tract infection, were treated with 20 mg/kg co-trimoxazole twice daily for five days. Parasitaemia (mean clearance time 2.7 days) and symptoms were rapidly abolished and improvement was maintained during follow-up for 14 days. Co-trimoxazole may be an effective single treatment for febrile illness in young children in areas where malaria is endemic, resources are few, and diagnosis must rely on clinical findings alone.

摘要

在马拉维评估了复方新诺明治疗5岁以下儿童恶性疟原虫血症的疗效。46名患有恶性疟原虫血症的儿童,其中37%还符合急性下呼吸道感染的临床诊断标准,接受每日两次、每次20mg/kg复方新诺明治疗,持续五天。疟原虫血症(平均清除时间2.7天)和症状迅速消除,且在14天的随访期间保持改善。在疟疾流行、资源匮乏且诊断必须仅依靠临床发现的地区,复方新诺明可能是治疗幼儿发热性疾病的一种有效单一疗法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验